People who have had a kidney transplant typically receive anti-rejection medications, such as
Simulect® (
basiliximab), to prevent transplant rejection. Simulect is given within two hours after kidney transplant surgery, and again four days later. It works by binding to certain white blood cells and preventing them from attacking the newly transplanted organ.
Simulect is specifically used to help prevent acute kidney rejection, which is rejection that occurs within the first six months of receiving a donor kidney. It is approved for use in adults and children as young as one year old.
(For more details, click Simulect Uses. This Web page offers a closer look at how this medication works to prevent transplant rejection, and also lists some of Simulect's unapproved uses.)
HealthSavvy Sign In
|